In a nutshell This study examined the safety and effectiveness of ticagrelor (Brilinta) in patients with multi-vessel coronary disease (MVD) who had a previous heart attack. It was determined that ticagrelor reduced the risk of major adverse cardiac events (MACE), but increased the risk of certain types of bleeding. Some background Coronary...
Read MoreIs ticagrelor effective in people with multi-vessel coronary artery disease?
